Ocular Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Ocular Therapeutix
OCUL Stock  USD 6.99  1.89  21.28%   
Ocular Therapeutix's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Ocular Therapeutix's valuation are provided below:
Gross Profit
-151.7 M
Market Capitalization
1.5 B
Enterprise Value Revenue
24.4622
Revenue
52 M
Earnings Share
(1.42)
There are over one hundred nineteen available trending fundamental ratios for Ocular Therapeutix, which can be analyzed over time and compared to other ratios. We recommend to check out Ocular Therapeutix's recent fundamental drivers against the all of the trends between 2010 and 2026. Market Cap is expected to rise to about 2.4 B this year. Enterprise Value is expected to rise to about 1.7 B this year

Ocular Therapeutix Total Revenue

54.41 Million

Check Ocular Therapeutix financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Ocular Therapeutix's main balance sheet or income statement drivers, such as Depreciation And Amortization of 4.6 M, Selling General Administrative of 67.6 M or Selling And Marketing Expenses of 56.6 M, as well as many indicators such as Price To Sales Ratio of 41.67, Dividend Yield of 0.0 or PTB Ratio of 3.65. Ocular financial statements analysis is a perfect complement when working with Ocular Therapeutix Valuation or Volatility modules.
  
Build AI portfolio with Ocular Stock
Check out the analysis of Ocular Therapeutix Correlation against competitors.
For more information on how to buy Ocular Stock please use our How to buy in Ocular Stock guide.

Ocular Therapeutix Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets848.5 M808.1 M208.7 M
Slightly volatile
Short and Long Term Debt Total45.2 M79.8 M37 M
Slightly volatile
Other Current Liabilities46 M43.8 M14.4 M
Slightly volatile
Total Current Liabilities53.3 M50.8 M19.6 M
Slightly volatile
Other Liabilities18.3 M22.8 M15.6 M
Slightly volatile
Property Plant And Equipment Net25.5 M24.3 M10.4 M
Slightly volatile
Accounts Payable3.3 M4.2 M2.7 M
Slightly volatile
Cash773.9 M737.1 M172.6 M
Slightly volatile
Non Current Assets Total13.5 M25.9 M11 M
Slightly volatile
Non Currrent Assets Other1.8 M1.9 M1.5 M
Slightly volatile
Other Assets1.091.151.4 M
Very volatile
Long Term Debt38.8 M71.3 M31.6 M
Slightly volatile
Cash And Short Term Investments773.9 M737.1 M181.2 M
Slightly volatile
Net Receivables32.2 M30.6 M10.6 M
Slightly volatile
Common Stock Shares Outstanding196.6 M187.2 M60.9 M
Slightly volatile
Liabilities And Stockholders Equity848.5 M808.1 M208.7 M
Slightly volatile
Non Current Liabilities Total75.7 M102.9 M69.2 M
Slightly volatile
Other Current Assets11.4 M10.9 M4.2 M
Slightly volatile
Total Liabilities97.1 M153.7 M86.9 M
Slightly volatile
Property Plant And Equipment Gross54.4 M51.8 M16.3 M
Slightly volatile
Total Current Assets821.2 M782.1 M196.9 M
Slightly volatile
Short Term Debt2.9 M2.8 M3.3 M
Very volatile
Property Plant Equipment7.1 M11.3 M6.5 M
Slightly volatile
Current Deferred Revenue14.7 M14 M6.1 M
Slightly volatile
Common Stock Total Equity5.3 K9.2 K4.8 K
Slightly volatile
Long Term Debt Total33.7 M62.1 M31.4 M
Slightly volatile
Capital Surpluse424.2 M750 M384.8 M
Slightly volatile
Inventory3.7 M3.6 M1.1 M
Slightly volatile
Deferred Long Term Liabilities6.9 M7.3 M10.1 M
Pretty Stable
Short and Long Term Debt7 M9.5 M6.1 M
Slightly volatile
Net Invested Capital761.9 M725.6 M167.7 M
Slightly volatile
Net Working Capital767.9 M731.3 M171.4 M
Slightly volatile
Capital Stock11.4 K22 K7.4 K
Slightly volatile
Capital Lease Obligations6.6 M5.6 M9.1 M
Slightly volatile

Ocular Therapeutix Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization4.6 M4.4 M2 M
Slightly volatile
Selling General Administrative67.6 M64.4 M25.8 M
Slightly volatile
Selling And Marketing Expenses56.6 M53.9 M18.8 M
Slightly volatile
Total Revenue54.4 M51.8 M20.8 M
Slightly volatile
Other Operating Expenses338.1 M322 M103 M
Slightly volatile
Research Development207 M197.1 M56 M
Slightly volatile
Cost Of Revenue3.4 M6.6 M2.7 M
Slightly volatile
Total Operating Expenses331.2 M315.4 M100.6 M
Slightly volatile
Preferred Stock And Other Adjustments8.8 K9.9 K10.8 K
Slightly volatile
Interest Income19.3 M18.4 M4.4 M
Slightly volatile
Reconciled Depreciation3 M4.3 M2.3 M
Slightly volatile

Ocular Therapeutix Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation45.3 M43.2 M12.8 M
Slightly volatile
Begin Period Cash Flow413.4 M393.7 M107.2 M
Slightly volatile
Depreciation2.2 M4.3 M1.8 M
Slightly volatile
Capital Expenditures12.6 M12 M3.3 M
Slightly volatile
Total Cash From Financing Activities589.8 M561.7 M135 M
Slightly volatile
End Period Cash Flow775.6 M738.7 M173.8 M
Slightly volatile
Sale Purchase Of Stock1.7 M1.6 M617.6 K
Slightly volatile
Change To Liabilities1.7 M1.2 M1.2 M
Slightly volatile
Issuance Of Capital Stock568.2 M541.2 M133 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio41.6743.863760
Slightly volatile
Days Sales Outstanding282216415
Slightly volatile
Stock Based Compensation To Revenue0.790.83335.8089
Slightly volatile
Capex To Depreciation1.792.77821.5059
Pretty Stable
EV To Sales29.6231.1799402
Slightly volatile
Inventory Turnover2.641.84462.0137
Slightly volatile
Days Of Inventory On Hand204198268
Slightly volatile
Payables Turnover2.161.58261.7458
Pretty Stable
Sales General And Administrative To Revenue1.181.242229.5375
Slightly volatile
Research And Ddevelopement To Revenue3.613.803312.3798
Slightly volatile
Capex To Revenue0.220.23184.2759
Slightly volatile
Cash Per Share3.813.93644.0251
Slightly volatile
Days Payables Outstanding2192316.4 K
Slightly volatile
Income Quality1.150.77041.3612
Pretty Stable
Current Ratio16.1615.39448.9107
Pretty Stable
Receivables Turnover1.611.69083.2611
Very volatile
Capex Per Share0.08510.06410.0768
Slightly volatile
Revenue Per Share0.210.27680.2157
Slightly volatile
Interest Debt Per Share0.340.36290.9748
Slightly volatile
Debt To Assets0.09380.09870.2469
Pretty Stable
Operating Cycle471414589
Slightly volatile
Days Of Payables Outstanding2192316.4 K
Slightly volatile
Ebt Per Ebit1.170.98491.0602
Very volatile
Quick Ratio16.0915.32438.8749
Pretty Stable
Net Income Per E B T0.770.870.9452
Slightly volatile
Cash Ratio15.2314.50736.958
Slightly volatile
Days Of Inventory Outstanding204198268
Slightly volatile
Days Of Sales Outstanding282216415
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.161.05861.0524
Slightly volatile
Fixed Asset Turnover1.22.13141.2454
Slightly volatile
Debt Ratio0.09380.09870.2469
Pretty Stable
Price Sales Ratio41.6743.863760
Slightly volatile
Asset Turnover0.07540.06410.0772
Slightly volatile
Gross Profit Margin0.620.87310.7195
Slightly volatile

Ocular Therapeutix Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap2.4 B2.3 B568.5 M
Slightly volatile
Enterprise Value1.7 B1.6 B435.1 M
Slightly volatile

Ocular Fundamental Market Drivers

Ocular Upcoming Events

4th of March 2024
Upcoming Quarterly Report
View
13th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
4th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Ocular Therapeutix Financial Statements

Ocular Therapeutix investors utilize fundamental indicators, such as revenue or net income, to predict how Ocular Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue14 M14.7 M
Total Revenue51.8 M54.4 M
Cost Of Revenue6.6 M3.4 M
Stock Based Compensation To Revenue 0.83  0.79 
Sales General And Administrative To Revenue 1.24  1.18 
Research And Ddevelopement To Revenue 3.80  3.61 
Capex To Revenue 0.23  0.22 
Revenue Per Share 0.28  0.21 
Ebit Per Revenue(5.21)(5.47)

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Prophet
When determining whether Ocular Therapeutix is a strong investment it is important to analyze Ocular Therapeutix's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Ocular Therapeutix's future performance. For an informed investment choice regarding Ocular Stock, refer to the following important reports:
How To Invest In Ocular
Details
Is Ocular Stock a good investment?
Details
What is Ocular Therapeutix's Net Worth?
Details
Largest Pharmaceuticals Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of Ocular Therapeutix Correlation against competitors.
For more information on how to buy Ocular Stock please use our How to buy in Ocular Stock guide.
You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ocular Therapeutix. Anticipated expansion of Ocular directly elevates investor willingness to pay premium valuations. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Ocular Therapeutix assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share
(1.42)
Revenue Per Share
0.277
Quarterly Revenue Growth
(0.22)
Return On Assets
(0.27)
Return On Equity
(0.55)
Ocular Therapeutix's market price often diverges from its book value, the accounting figure shown on Ocular's balance sheet. Smart investors calculate Ocular Therapeutix's intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Since Ocular Therapeutix's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
It's important to distinguish between Ocular Therapeutix's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Ocular Therapeutix should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, Ocular Therapeutix's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY